Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bode, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bode, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Introduction

E-mail address: christoph.bode@uniklinik-freiburg.de

The first 10% of the full text of this article appears below.

Atherothrombotic disease is the leading cause of cardiovascular disorders and related deaths worldwide; its prevalence is increasing in society primarily because of the aging demographic. Humans have evolved a highly efficient coagulation system to prevent unwanted bleeding, but this system is also reactive with damaged endothelium and atherosclerotic plaque. These can lead to platelet activation, and ultimately clot formation, resulting in thrombotic events. Antiplatelet therapies have therefore become a cornerstone of treatment for atherothrombotic disease, and the benefits of currently available antiplatelet agents (including aspirin, irreversible thienopyridine ADP receptor antagonists, and glycoprotein . . . [Full Text of this Article]

Christoph Bode

University Hospital
Freiburg
Germany


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?